Shifting the clinical paradigm: Copper versus silver wound dressings - Where we are and what we are looking for

The development of nanoparticle-based wound dressings marks a significant advancement in the management of chronic and non-healing wounds. Silver-based dressings have been used in wound management due to their strong antimicrobial properties. However, their clinical effectiveness depends on formulation, concentration, and duration of use. Recently, copper oxide dressings (CODs) have emerged as a novel alternative, offering both antimicrobial and regenerative benefits. We reviewed clinical studies, meta-analyses, and cost-effectiveness analyses on silver nanoparticle (AgNP), ionic silver, nanocrystalline silver, and copper oxide dressings across various wound types, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, and burns. Emphasis was placed on dressing formulations, silver or copper concentrations, clinical efficacy, safety, and cost-effectiveness. Traditional silver formulations, such as silver sulfadiazine (1%) and silver nitrate (0.5%), demonstrate antimicrobial activity but are limited by cytotoxicity and lack of long-term healing benefits. Nanocrystalline silver and ionic silver hydrofiber dressings provide sustained release, proving most effective in infection-prone and early inflammatory phases. Enhanced formulations (Aquacel® Ag + Extra™) show promise in treating biofilm-related wounds but need more robust data. By contrast, CODs have demonstrated antimicrobial efficacy alongside stimulation of angiogenesis, fibroblast proliferation, and extracellular matrix remodeling. Early clinical evidence suggests that CODs may accelerate healing in refractory wounds and offer cost advantages over negative pressure therapy, though large-scale trials remain limited. Silver dressings, particularly nanocrystalline and ionic hydrofiber formulations, remain clinically useful for infection control and short-term wound management, while older silver salts are less favorable due to toxicity and limited efficacy. CODs represent a biologically attractive alternative with dual antimicrobial and regenerative properties. Nonetheless, the current body of evidence is insufficient to declare a paradigm shift in wound healing, and CODs should presently be regarded as promising adjuncts pending validation in high-quality randomized trials.